JCAD promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting LATS2 kinase activity

Juan Ye, Tian Sheng Li, Gang Xu, Yi Ming Zhao, Ning Ping Zhang, Jia Fan, Jian Wu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Nonalcoholic steatohepatitis-associated hepatocellular carcinoma (NASH-HCC) is a malignancy whose incidents are rapidly increasing. However, the mechanisms that drive development of HCC in a steatotic microenvironment remain unknown. Here we report that the obesity-associated protein JCAD is expressed at significantly higher levels in human NASH-HCC specimens compared with pericarcinoma specimens. High JCAD expression was verified in multiple hepatoma cell lines. Forced overexpression of JCAD in hepatoma cells promoted tumor growth and proliferation, whereas JCAD silencing yielded opposite effects. JCAD interacted with the kinase domain of the tumor suppressor kinase LATS2, a core component of the Hippo signaling pathway. JCAD overexpression inhibited the ability of LATS2 to phosphorylate YAP in this pathway, in turn upregulating CCND1 and GLI2 to promote hepatoma cell proliferation. JCAD was induced by fatty acid overload in hepatic cells and was highly expressed in a mouse model of NASH-precarcinoma lesions, where the ratio of phospho-YAP to YAP was decreased. In human NASH-HCC specimens, JCAD expression and YAP phosphorylation patterns paralleled with the mouse model. Our findings illuminate a new role for JCAD and its critical interplay in the Hippo signaling cascade during the transition of NASH to HCC, with potential implications for therapeutic development in this setting.

Original languageEnglish (US)
Pages (from-to)5287-5300
Number of pages14
JournalCancer Research
Volume77
Issue number19
DOIs
StatePublished - Oct 1 2017
Externally publishedYes

Fingerprint

Liver Neoplasms
Hepatocellular Carcinoma
Phosphotransferases
Neoplasms
Non-alcoholic Fatty Liver Disease
Hepatocytes
Fatty Acids
Obesity
Phosphorylation
Cell Proliferation
Cell Line
Growth
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

JCAD promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting LATS2 kinase activity. / Ye, Juan; Li, Tian Sheng; Xu, Gang; Zhao, Yi Ming; Zhang, Ning Ping; Fan, Jia; Wu, Jian.

In: Cancer Research, Vol. 77, No. 19, 01.10.2017, p. 5287-5300.

Research output: Contribution to journalArticle

Ye, Juan ; Li, Tian Sheng ; Xu, Gang ; Zhao, Yi Ming ; Zhang, Ning Ping ; Fan, Jia ; Wu, Jian. / JCAD promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting LATS2 kinase activity. In: Cancer Research. 2017 ; Vol. 77, No. 19. pp. 5287-5300.
@article{e2dc2924d9e64b37a85d978d3833faa1,
title = "JCAD promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting LATS2 kinase activity",
abstract = "Nonalcoholic steatohepatitis-associated hepatocellular carcinoma (NASH-HCC) is a malignancy whose incidents are rapidly increasing. However, the mechanisms that drive development of HCC in a steatotic microenvironment remain unknown. Here we report that the obesity-associated protein JCAD is expressed at significantly higher levels in human NASH-HCC specimens compared with pericarcinoma specimens. High JCAD expression was verified in multiple hepatoma cell lines. Forced overexpression of JCAD in hepatoma cells promoted tumor growth and proliferation, whereas JCAD silencing yielded opposite effects. JCAD interacted with the kinase domain of the tumor suppressor kinase LATS2, a core component of the Hippo signaling pathway. JCAD overexpression inhibited the ability of LATS2 to phosphorylate YAP in this pathway, in turn upregulating CCND1 and GLI2 to promote hepatoma cell proliferation. JCAD was induced by fatty acid overload in hepatic cells and was highly expressed in a mouse model of NASH-precarcinoma lesions, where the ratio of phospho-YAP to YAP was decreased. In human NASH-HCC specimens, JCAD expression and YAP phosphorylation patterns paralleled with the mouse model. Our findings illuminate a new role for JCAD and its critical interplay in the Hippo signaling cascade during the transition of NASH to HCC, with potential implications for therapeutic development in this setting.",
author = "Juan Ye and Li, {Tian Sheng} and Gang Xu and Zhao, {Yi Ming} and Zhang, {Ning Ping} and Jia Fan and Jian Wu",
year = "2017",
month = "10",
day = "1",
doi = "10.1158/0008-5472.CAN-17-0229",
language = "English (US)",
volume = "77",
pages = "5287--5300",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - JCAD promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting LATS2 kinase activity

AU - Ye, Juan

AU - Li, Tian Sheng

AU - Xu, Gang

AU - Zhao, Yi Ming

AU - Zhang, Ning Ping

AU - Fan, Jia

AU - Wu, Jian

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Nonalcoholic steatohepatitis-associated hepatocellular carcinoma (NASH-HCC) is a malignancy whose incidents are rapidly increasing. However, the mechanisms that drive development of HCC in a steatotic microenvironment remain unknown. Here we report that the obesity-associated protein JCAD is expressed at significantly higher levels in human NASH-HCC specimens compared with pericarcinoma specimens. High JCAD expression was verified in multiple hepatoma cell lines. Forced overexpression of JCAD in hepatoma cells promoted tumor growth and proliferation, whereas JCAD silencing yielded opposite effects. JCAD interacted with the kinase domain of the tumor suppressor kinase LATS2, a core component of the Hippo signaling pathway. JCAD overexpression inhibited the ability of LATS2 to phosphorylate YAP in this pathway, in turn upregulating CCND1 and GLI2 to promote hepatoma cell proliferation. JCAD was induced by fatty acid overload in hepatic cells and was highly expressed in a mouse model of NASH-precarcinoma lesions, where the ratio of phospho-YAP to YAP was decreased. In human NASH-HCC specimens, JCAD expression and YAP phosphorylation patterns paralleled with the mouse model. Our findings illuminate a new role for JCAD and its critical interplay in the Hippo signaling cascade during the transition of NASH to HCC, with potential implications for therapeutic development in this setting.

AB - Nonalcoholic steatohepatitis-associated hepatocellular carcinoma (NASH-HCC) is a malignancy whose incidents are rapidly increasing. However, the mechanisms that drive development of HCC in a steatotic microenvironment remain unknown. Here we report that the obesity-associated protein JCAD is expressed at significantly higher levels in human NASH-HCC specimens compared with pericarcinoma specimens. High JCAD expression was verified in multiple hepatoma cell lines. Forced overexpression of JCAD in hepatoma cells promoted tumor growth and proliferation, whereas JCAD silencing yielded opposite effects. JCAD interacted with the kinase domain of the tumor suppressor kinase LATS2, a core component of the Hippo signaling pathway. JCAD overexpression inhibited the ability of LATS2 to phosphorylate YAP in this pathway, in turn upregulating CCND1 and GLI2 to promote hepatoma cell proliferation. JCAD was induced by fatty acid overload in hepatic cells and was highly expressed in a mouse model of NASH-precarcinoma lesions, where the ratio of phospho-YAP to YAP was decreased. In human NASH-HCC specimens, JCAD expression and YAP phosphorylation patterns paralleled with the mouse model. Our findings illuminate a new role for JCAD and its critical interplay in the Hippo signaling cascade during the transition of NASH to HCC, with potential implications for therapeutic development in this setting.

UR - http://www.scopus.com/inward/record.url?scp=85031495316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031495316&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-17-0229

DO - 10.1158/0008-5472.CAN-17-0229

M3 - Article

C2 - 28775168

AN - SCOPUS:85031495316

VL - 77

SP - 5287

EP - 5300

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 19

ER -